Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer

Rutger J. Dost*, Andor W. J. M. Glaudemans, Anthonius J. Breeuwsma, Igle J. de Jong

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)

Abstract

Purpose Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT.

Methods Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT. Results During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naive patients.

Conclusion We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naive patients.

Original languageEnglish
Pages (from-to)S41-S47
Number of pages7
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume40
DOIs
Publication statusPublished - Jul-2013

Keywords

  • Recurrent prostate cancer
  • Choline PET/CT
  • Androgen deprivation therapy
  • Hormone-naive prostate cancer
  • Castration-resistant prostate cancer
  • POSITRON-EMISSION-TOMOGRAPHY
  • RADICAL PROSTATECTOMY
  • BIOCHEMICAL RECURRENCE
  • KINASE-ALPHA
  • CELL-LINES
  • METABOLISM
  • DEPENDS
  • RELAPSE
  • BETA

Cite this